This information is intended for Canadian residents.
Sanofi is a leader in the global pharmaceutical market, with an extensive line of prescription medicines. Links to comprehensive information about our pharmaceutical products are listed below, most frequently in the form of a product monograph.This information has been approved by Health Canada and should be read and discussed in consultation with a health care professional.
Admelog™ and Admelog™ SoloSTAR®
(insulin lispro injection)
(coagulation factor IX (recombinant), Fc fusion protein)
(nilutamide)
(ipratropium bromide)
(teriflunomide)
(irbesartan, hydrochlorothiazide)
(irbesartan)
(calcitonin-salmon)
(clofarabine for injection)
(clomiphene citrate)
(podofilox topical solution)
(danazol)
(meperidine hydrocholoride)
(glyburide)
(dupilumab)
(leuprolide acetate)
(antihemophilic factor (recombinant BDD), Fc fusion protein )
(oxaliplatin)
(agalsidase beta)
(rasburicase)
(sodium ferric gluconate)
(metronidazole)
(metronidazole, nystatin)
(fludarabine phosphate)
Trademark of Merck Santé s.a.s. Commercialized in Canada by sanofi-aventis. (metformin hydrochloride)
(sodium polystyrene sulfonate)
(insuline glargine)
For more information, contact Sanofi Canada at 1-888-852-6887(furosemide)
(furosemide)
(cemiplimab)
(enoxaparin sodium)
(acetaminophen, codeine phosphate, doxylamine succinate)
(plerixafor injection)
(dronedarone tablets)
- Product Monograph
- Suggested prescriber checklist
- Healthcare professional information sheet
- Safety information for the public - Aug. 4 2011 (permanent atrial fibrillation)
- Safety Information for healthcare professionals - July 29 2011 (permanent atrial fibrillation)
- Safety information for the public - March 15 2011 (liver injury)
- Safety information for healthcare professionals - March 10 2011 (hepatocellular liver injury)
- Information for health professionals (PALLAS study and pulmonary safety)
- Information for the public (PALLAS study)
(sodium aurothiomalate)
(alglucosidase alfa)
(sodium cromoglycate)
(triamcinolone acetonide)
Trademark of G. Pohl-Boskamp GmbH & Co. Commercialized in Canada by sanofi-aventis. (nitroglycerin)
(hydrocodone bitartrate, phenylephrine hydrochloride)
(hydrocodone bitartrate, phenylephrine hydrochloride)
(methotrimeprazine)
(prednisolone sodium phosphate)
(hydroxychloroquine sulfate)
(alirocumab)
(primaquine phosphate)
(sevelamer hydrochloride tablets)
(sevelamer carbonate tablets)
(calcium polystyrene sulfonate)
(rifampin)
(riluzole)
(disopyramide)
(acebutolol hydrochloride)
(adhesion barrier)
(framycetin sulphate, gramicidin, dexamethasone)
(insulin glargine and lixisenatide for injection)
(buserelin acetate)
(buserelin acetate implant)
(pentazocine hydrochloride)
(docetaxel)
(anti-thymocyte globulin)
(thyrotropin alpha)
(hydrocodone resin complex, phenyltoloxamine resin complex)
(alfuzosin hydrochloride)
(metolazone)